We have used an enzyme-linked immunoassay technique to quantify human C-reactive protein (CAP). In this assay phosphorylethanolamine is covalently linked to polystyrene wells. Serum or plasma specimens are diluted 961-fold and assayed. After Ca2-dependent binding of CAP to the plates, the complex is reacted with peroxidase-labeled anti-CAP antibody. The response varies linearly with CRP concentrations between 10 and 160 mg/L; the detection limit is 0.34 ng per well. The results correlate well (r 0.90) with those of rate nephelometry. This new method can be automated, is not subject to interferences or cross reactivity, is highly reproducible, has low background values, and can be carried out at room temperature. Here we describe a new immunoenzymatic method for quantifying human CRP by binding to PE-coated solidphase, soon to be commercially available as GENUS#{174} ClIP assay (Invesgen, Madrid, Spain). This approach has several advantages over other methods: #{149} higher sensitivity and specificity #{149} easy automation for assaying a large number of samples (as with any other assay involving microtiter plates) #{149} no interference from other serum constituents: rheumatoid factor, serum amyloid protein (SAP), plasma, IgG, or hemoglobin (hemolysis) #{149} total 2-h incubation at room temperature, with few steps for reconstitution of reagents #{149} low background and wide range of assay linearity
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Materials and Methods

Materials
Purification of CRP:
We used the method of Pontet et al. (9) to purify CRP. In brief, the method is as follows. Human ascitic fluid was dialyzed against a solution containing, per liter, 20 mmol of Tris, 0.1 mol of NaCl, and 10 mmol of CaCl2 (pH 8), and passed through a 8 x 3 cm column of Sepharose 4B (Pharmacia, Uppsala, Sweden) connected to another column (7 x 1.2 cm) of agarose with immobilized 2-anunoethyl dihydrogen phosphate (Pierce Chemical Co.,
Rockford, IL).
Up to 500 mL of ascitic fluid could be processed each time. After washing the combined columns with the dialysis buffer, we separately eluted SAP and CRP from each of the two columns, using a solution containing 20 mmol of Tris, 0.1 mol of NaCl, and 20 mmol of citrate per liter (pH 8): "TSC eluent." Two peaks were usually eluted from the aminoethyl dihydrogen phosphate column; only the second peak reacted with anti-CRP antisera (Biomerieux, Charbonni#{232}res les Bains, France) by immunodiffusion. The fractions with ClIP activity were pooled and dialyzed against the Ca2-containing buffer described above. After discarding the precipitated material that appeared upon dialysis, we rechromatographed the ClIP on the combined columns and separately eluted this protein from the aminoethyl dihydrogen phosphate column as above. The fractions with ClIP activity were pooled and kept in the TSC eluent at 4#{176}C.
We used the following medium for immunodiffusion: borate 200 mmol/L, NaCl 75 mmol/L, CaCl2 2.5 mmol/L, agar 10 g/L, and thimerosal 100 mgfL (pH 8). We calculated CR? concentrations from absorbance at 280 nm, using an absorptivity (for 1 g/L solutions) of 1.95 (10). Polyacrylamide gel electrophoresis (PAGE) with sodium dodecyl sulfate and (3-mercaptoethanol demonstrated only one band at 21 kDa. Pooled CRP-free human serum, and standards: Serum from at least 100 healthy persons was collected and pooled to a total volume of 500 mL. The sera were negative for both hepatitis B surface antigen ("Monolisa"; Pasteur, MarnesLa-Coquette, France) and H1V antibodies ("Elavia"; Pasteur). This pooled serum did not give a precipitation band by immunodiffusion against the anti-CR? antisera but, when measured by CR? binding to PE-coated wells, gave a positive result (quantified at 5 mg/L). We then dialyzed the serum against the dialysis buffer and passed the dialysate through a 3.5 x 2.6 cm column of agarose-immobilized 2-aminoethyl dihydrogen phosphate. Any CRP in the eluent, as measured by CR? binding to PE, was now below the detection limit of the assay (1 mg/L). We prepared standards by adding purified CRP to the dilution buffer and to diluted (961-fold) CRP-free pooled human serum.
Serum samples for correlation studies:
The blood samples from patients or from healthy controls (3-6 mL each) were allowed to clot. The sera were separated by centrifugation and frozen at -20 #{176}C until use. The samples were to be assayed by four test methods: (a) latex agglutination, 
4).
After washing the plates we kept them vacuum sealed at 4 #{176}C until use. Under these conditions, the plates were stable for at least a year. Goat anti-human CR? antiserum (Biomerieux) was purified on an affinity column made with purified CRP. The purified anti-CR? antibodies were coupled to peroxidase by the glutaraldehyde method (12) .
The assay procedure is as follows: dilute the samples 961-fold in dilution buffer (per liter, 0.2 mol of sodium borate, 75 mmol of NaCl, 2 mmol of CaC12, 0.24 mmol of thimerosal, 10 g of bovine serum albumin, and 0.5 g of Tween 20, pH 7.5). 492 and 620 nm. We used the absorbance at 620 nm to correct for individual nonsignificant differences between wells.
Interference assays: We measured the analytical recovery of purified CR? added to sera containing potential interferents. Each sample was tested in duplicate by measuring the ClIP binding to PE. Six or 12 L of a 1 g/L solution of pure CRP was added to 100 L of serum (see Table 3 Increasing concentrations of other potentially interfering substances were added to various human sera; we measured CRP concentrations before and after these additions.
The concentration of human IgG (Nordic, Tilburg, The Netherlands) was adjusted by measuring the absorbance at 280 nm and using #{128} = 1.4. We added the human IgG to 961-fold dilutions of four different sera to give final concentrations equivalent to 9.6 and 96 g/L [normal concentration of IgG in human serum, 10-15 g/L (13)1.
Human hemoglobin was isolated by repeated freeze-thaw treatment of packed human erythrocytes, followed by cen-
triftigation.
The concentration was adjusted by measuring the absorbance of heme at 403 nm and using a value of 80 for the millimolar absorptivity.
We added human hemoglobin to the serum to give final concentrations of 0.7, 1.4, and
g/L [the maximum hemoglobin concentration in hemolysis is about 4 g/L (14)].
Human SAP was purified as follows: 1500 mL of human ascitic fluid was dialyzed and passed through a column of For all the above interference measurements, we calculated the results as (amount found after addition of substance/ initial amount)
x 100. Sera with differing CRP contents were measured in duplicate by the same analyst at 961-and 96-fold dilutions on eight separate days during two weeks. In other experiments we measured sera diluted 961-and 480-fold. The CRP concentrations were calculated from the standard curve, taking the dilution factor into account. Analytical recovery was calculated as follows: (average CRP concentration at 96-or 480-fold dilution/average ClIP concentration at 961-fold dilution) x 100. The background-corrected absorbances obtained in 11 assays with dilution buffer, the ClIP zero standard, and pooled human serum negative for ClIP (diluted 961-fold) were 0.013 ±0.014,0.035 ±0.019, and 0.032 ±0.016, respectively (mean ± SD). Assuming a normal distribution, we calculated the sensitivity and the detection limit of the assay. The sensitivity, defined as the lowest concentration that can be differentiated from the zero standard with 95% confidence, was 3.3 mg/L (0.34 ng per well). The detection limit, defined as the lowest concentration that can be differentiated from the results for the dilution buffer with 95% confidence, was 1 mg/L (0.1 ng per well). Table 1 summarizes between-and within-run CVs. By assaying 170 samples in duplicate in four separate assays and dividing the samples into six concentration groups, we calculated that the CV varied between 3.7% and 8.3% for samples with CRP concentrations ranging from 0 to 160 mgfL.
The CR?-positive sara, as determined by latex assay (method a), had an average CR? concentration of 37.6 mg/L (n = 99) as quantified by CR? binding to PE ( Table 2) 
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We analyzed 170sera in duplicate in four separate assays and groupedthe results by CAP concentration. Average CV of independent duplicates for each group of sern. The normal CRP concentration in adults' sara can also be measured by pooling a great number of sara from healthy adults and measuring the resulting CR? concentration. For a 500-mL specimen of serum obtained by pooling 3-5 mL of individual samples collected over a three-week period, the mean CRP content was 5.6 (SD 1) mg/L (n = 6).
Results of some clinical studies with sara from patients with an increased ClIP content are shown in Figure 3 . CR? concentrations of 20 to 80 mg/L were found in patients with various diagnosed diseases. Most healthy adults had CR? concentrations 6 mg/L. Table 3 summarizes the recovery of purified CR? added to various sara.
Analytical Recovery Studies and Possible interferences
Measuring 10 samples with a positive rheumatoid factor reaction to latex, with and without added CR?, showed a correlation between the expected (y) and found (x) values of r = 0.953 (y = 1.09x -6.1 mg/L).
The possible interferences due to normal serum constituents were studied by assaying CR? at serum dilutions of 96-, 480-, and 961-fold (Table 3 Sensitivity and specificity were calculated by assuming a cutoff value of 6 mg/b such as the one used in the commercially available latex test (assay a). Results are summarized in Table 5 .
Discussion
The CR? binding to solid-phase PE provides an alternative for quantitative assessment of human CR? that does not involve precipitation, agglutination, or radioactivity.
The present method (Figure 1 (Table 1) , as compared with 4.5% to 9.3% for method c (18) . The between-run CV for method d ranges from 3.7% to 11.2% (Table 1 and Table 2 ), compared with 6.6% to 11.6% for method c (18) .
The fact that there are lower between-nm CVs in Table 2 than the between-run CVs on Table 1 could be the result of the larger n (8 in Table 1 , 14-50 in Table 2 ). Between-run CVs in Table 2 are very similar to the within-run CVs in Table 1 (n = 54).
The present method offers a low incidence of false positives. When CR?-negative sara were assayed in within-run (Table 1) . No data on this have been reported for methods a, b, or c. All the characteristics mentioned above make the present assay method suitable for reliable quantification of normal and pathological CR? concentrations in serum, plasma, or other biofluids.
The cutoff value for distinguishing negative from positive by this technique, evaluated graphically, is 10 mg/b ( Figure  2A ). The 95% confidence limit, assuming normal distribution ( Figure 2B Methods (a, b, C) By nephelometry Table 3 shows the absence of gross interferences from normal serum components, rheumatoid factor, hyperlipemic serum, IgG, hemoglobin, and SAP. Added heparin, citrate, or EDTA, to obtain plasma, did not interfere with the assay. Method c, on the other hand, is subject to interferences from hyperlipemic serum; no other possible interferences have been studied with regard to methods b or c (11) .
In all, 148 different sara were analyzed by methods a, b, c, and d (Tables 4 and 5 ). The correlations, slopes, and intercepts between these assays and their respective means indicate that CRP binding to PE is a useful technique for determining CR? concentrations in clinical specimens. The sara shown to be positive by methods b and c were respectively 91% and 100% positive by method d. However, only 79% of the sera positive by a were positive by d, most probably due to the high incidence of false positives in method a (1). The sara negative by c were also between 51 and 71% negative by d, reflecting the fact that all values by c were slightly lower than the values by d. This discrepancy might be due to differences in the calibrators or, more probably, to the low dilution-higher background in c (sara are diluted sixfold in c, 961-fold in d). Similar problems are found at lower dilutions in d (Table 3 : results for 96-fold dilutions are 68% of those for 961-fold diluted samples).
With this new method we could assay 41 serum samples for CR?, in duplicate, in about 3 h (a rate similar to method b). In comparison with method c the assay time for 40 specimens in single determinations is about 2 h.
Ten-microliter
samples of serum suffice for making the measurements, similar to that for method b, but better than the 1-2 mL required in method c. This micro-sample volume We thank Angeles Samino Moreno for her technical assistance.
